Legionella und Legionellose

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Martin Kolditz - , Department of internal Medicine I, University Hospital Carl Gustav Carus Dresden (Author)
  • Christian Lück - , Institute of Medical Microbiology and Virology, University Hospital Carl Gustav Carus Dresden (Author)

Abstract

Diagnosed and reported Legionella pneumonias are slightly increasing during recent years. This might at least partially be due to more frequently used diagnostic tests.In severe pneumonia, nucleic acid amplification based methods should supplement the L. pneumophila serogroup-1 urinary antigen test because of their improved spectrum and sensitivity.Recent in vitro data suggest enhanced efficacy of levofloxacin when compared to macrolides. This complements recent clinical cohort data. Thus levofloxacin (750-1000 mg/d) is regarded the treatment of choice for confirmed legionellosis. Second line options are azithromycin or moxifloxacin. Treatment duration of 7 days should be sufficient in most cases.Development of resistance is rare and no routine resistance testing is necessary.

Translated title of the contribution
Legionella and Legionellosis

Details

Original languageGerman
Pages (from-to)1030-1033
Number of pages4
JournalDeutsche medizinische Wochenschrift (1946)
Volume144
Issue number15
Publication statusPublished - Aug 2019
Peer-reviewedYes

External IDs

ORCID /0000-0001-6022-6827/work/127321420
Scopus 85069809583

Keywords

Keywords

  • Anti-Bacterial Agents/pharmacology, Drug Resistance, Bacterial, Humans, Legionella/drug effects, Legionellosis/diagnosis, Levofloxacin/pharmacology